TY - JOUR
T1 - Observed and expected incidence of cervical cancer in Lusaka and the southern and western provinces of Zambia, 2007 to 2012
AU - Kalima, Mulele
AU - Lishimpi, Kennedy
AU - Meza, Jane L.
AU - Watanabe-Galloway, Shinobu
AU - Msadabwe, Susan C.
AU - Mwaba, Catherine K.
AU - Shibemba, Aaron L.
AU - Banda, Lewis
AU - Wood, Charles
AU - Chamberlain, Robert M.
AU - Soliman, Amr S.
N1 - Publisher Copyright:
Copyright © 2014 by IGCS and ESGO.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objectives: Cervical cancer is increasing but underestimated in developing countries. We calculated the observed and expected incidence of cervical cancer in Lusaka and Southern and Western provinces of Zambia. Methods/Materials: Data for 2007 to 2012were obtained for the 3 provinces. Data included age, residence, year of diagnosis, marital status, occupation, human immunodeficiency virus (HIV), stage, radiotherapy, and chemotherapy. Expected incidence in Southern and Western provinceswas calculated based on observed incidence for Lusaka province, adjusting for HIV. Results: Crude and age-standardized incidence rates (ASRs) in Lusaka were 2 to 4 times higher than incidence in the other 2 provinces. Lusaka had a rate of 54.1 per 105 and ASR of 82.1 per 105 in the age group of 15 to 49 years. The Southern province had a rate of 17.1 per 105 and ASR of 25.5 per 105; the Western province had a rate of 12.3 per 105 and ASR rate of 17.2 per 105. The observed cervical cancer incidence rates in the Southern and Western provinces were lower than the rate in Lusaka, possibly because of the uncertainty of underreporting/underdiagnosis or actual lower risk for reasons yet unclear. The HIV seroprevalence rates in patients from the 3 provinces were 46% to 93% higher than seroprevalence in the respective general populations. Conclusions: Cervical cancer is significantly underestimated in Zambia, and HIV has a significant role in pathogenesis. Future studies should establish methods for case ascertainment and better utilization of hospital- And population-based registries in Zambia and other similar developing countries.
AB - Objectives: Cervical cancer is increasing but underestimated in developing countries. We calculated the observed and expected incidence of cervical cancer in Lusaka and Southern and Western provinces of Zambia. Methods/Materials: Data for 2007 to 2012were obtained for the 3 provinces. Data included age, residence, year of diagnosis, marital status, occupation, human immunodeficiency virus (HIV), stage, radiotherapy, and chemotherapy. Expected incidence in Southern and Western provinceswas calculated based on observed incidence for Lusaka province, adjusting for HIV. Results: Crude and age-standardized incidence rates (ASRs) in Lusaka were 2 to 4 times higher than incidence in the other 2 provinces. Lusaka had a rate of 54.1 per 105 and ASR of 82.1 per 105 in the age group of 15 to 49 years. The Southern province had a rate of 17.1 per 105 and ASR of 25.5 per 105; the Western province had a rate of 12.3 per 105 and ASR rate of 17.2 per 105. The observed cervical cancer incidence rates in the Southern and Western provinces were lower than the rate in Lusaka, possibly because of the uncertainty of underreporting/underdiagnosis or actual lower risk for reasons yet unclear. The HIV seroprevalence rates in patients from the 3 provinces were 46% to 93% higher than seroprevalence in the respective general populations. Conclusions: Cervical cancer is significantly underestimated in Zambia, and HIV has a significant role in pathogenesis. Future studies should establish methods for case ascertainment and better utilization of hospital- And population-based registries in Zambia and other similar developing countries.
KW - Cervical cancer
KW - Developing countries
KW - Incidence
KW - Zambia
UR - http://www.scopus.com/inward/record.url?scp=84927726505&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927726505&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000325
DO - 10.1097/IGC.0000000000000325
M3 - Article
C2 - 25423318
AN - SCOPUS:84927726505
SN - 1048-891X
VL - 25
SP - 98
EP - 105
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 1
ER -